Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune checkpoint inhibitors and cardiovascular toxicity.
Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Lyon AR, et al. Among authors: larkin j. Lancet Oncol. 2018 Sep;19(9):e447-e458. doi: 10.1016/S1470-2045(18)30457-1. Lancet Oncol. 2018. PMID: 30191849 Free article. Review.
Treatment of brain metastases in patients with melanoma.
Fisher R, Larkin J. Fisher R, et al. Among authors: larkin j. Lancet Oncol. 2012 May;13(5):434-5. doi: 10.1016/S1470-2045(12)70118-3. Epub 2012 Mar 27. Lancet Oncol. 2012. PMID: 22456430 No abstract available.
Phase I/II RAF kinase inhibitors in cancer therapy.
Turajlic S, Ali Z, Yousaf N, Larkin J. Turajlic S, et al. Among authors: larkin j. Expert Opin Investig Drugs. 2013 Jun;22(6):739-49. doi: 10.1517/13543784.2013.797964. Epub 2013 May 6. Expert Opin Investig Drugs. 2013. PMID: 23642225 Review.
Axitinib in advanced renal-cell carcinoma.
Yousaf N, Larkin J. Yousaf N, et al. Among authors: larkin j. Lancet Oncol. 2013 Dec;14(13):1245-6. doi: 10.1016/S1470-2045(13)70499-6. Epub 2013 Oct 25. Lancet Oncol. 2013. PMID: 24206641 No abstract available.
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH Jr, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU. Larkin J, et al. Lancet Oncol. 2014 Apr;15(4):436-44. doi: 10.1016/S1470-2045(14)70051-8. Epub 2014 Feb 27. Lancet Oncol. 2014. PMID: 24582505 Clinical Trial.
The cost of ipilimumab toxicity: a single-centre analysis.
Yousaf N, Davidson M, Goode E, Thomas C, Hung R, Gore M, Larkin J. Yousaf N, et al. Among authors: larkin j. Melanoma Res. 2015 Jun;25(3):259-64. doi: 10.1097/CMR.0000000000000158. Melanoma Res. 2015. PMID: 25860328
Melanoma epidemiology, biology and prognosis.
Ali Z, Yousaf N, Larkin J. Ali Z, et al. Among authors: larkin j. EJC Suppl. 2013 Sep;11(2):81-91. doi: 10.1016/j.ejcsup.2013.07.012. EJC Suppl. 2013. PMID: 26217116 Free PMC article. Review. No abstract available.
Management of toxicities of immune checkpoint inhibitors.
Spain L, Diem S, Larkin J. Spain L, et al. Among authors: larkin j. Cancer Treat Rev. 2016 Mar;44:51-60. doi: 10.1016/j.ctrv.2016.02.001. Epub 2016 Feb 6. Cancer Treat Rev. 2016. PMID: 26874776 Review.
1,233 results